Patented small molecule inhibitors in the ubiquitin proteasome system

Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(®) (bortezomib) for the treatment of multiple myeloma and mantle cell lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Guédat, Philippe, Colland, Frédéric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2106365/
https://www.ncbi.nlm.nih.gov/pubmed/18047738
http://dx.doi.org/10.1186/1471-2091-8-S1-S14
_version_ 1782138473977741312
author Guédat, Philippe
Colland, Frédéric
author_facet Guédat, Philippe
Colland, Frédéric
author_sort Guédat, Philippe
collection PubMed
description Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(®) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; ).
format Text
id pubmed-2106365
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-21063652007-12-05 Patented small molecule inhibitors in the ubiquitin proteasome system Guédat, Philippe Colland, Frédéric BMC Biochem Review Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(®) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; ). BioMed Central 2007-11-22 /pmc/articles/PMC2106365/ /pubmed/18047738 http://dx.doi.org/10.1186/1471-2091-8-S1-S14 Text en Copyright © 2007 Guédat and Colland; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Guédat, Philippe
Colland, Frédéric
Patented small molecule inhibitors in the ubiquitin proteasome system
title Patented small molecule inhibitors in the ubiquitin proteasome system
title_full Patented small molecule inhibitors in the ubiquitin proteasome system
title_fullStr Patented small molecule inhibitors in the ubiquitin proteasome system
title_full_unstemmed Patented small molecule inhibitors in the ubiquitin proteasome system
title_short Patented small molecule inhibitors in the ubiquitin proteasome system
title_sort patented small molecule inhibitors in the ubiquitin proteasome system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2106365/
https://www.ncbi.nlm.nih.gov/pubmed/18047738
http://dx.doi.org/10.1186/1471-2091-8-S1-S14
work_keys_str_mv AT guedatphilippe patentedsmallmoleculeinhibitorsintheubiquitinproteasomesystem
AT collandfrederic patentedsmallmoleculeinhibitorsintheubiquitinproteasomesystem

Ejemplares similares